NEU Share Price

Open 0.08 Change Price %
High 0.08 1 Day 0.00 0.00
Low 0.08 1 Week -0.01 -11.11
Close 0.08 1 Month 0.02 33.33
Volume 195549 1 Year -0.02 -20.00
52 Week High 0.13
52 Week Low 0.04
NEU Important Levels
Resistance 2 0.08
Resistance 1 0.08
Pivot 0.08
Support 1 0.08
Support 2 0.08
ASX Australia Most Active Stocks
AGO 0.05 0.00%
AGO 0.05 0.00%
AGO 0.05 0.00%
VXR 0.01 0.00%
MOD 0.04 0.00%
MOD 0.04 0.00%
TLS 4.84 -0.21%
TLS 4.84 -0.21%
TLS 4.84 -0.21%
BUR 0.02 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
GBZ 0.02 100.00%
TMX 0.02 100.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
PMQ 0.03 50.00%
PYC 0.04 33.33%
GME 0.09 28.57%
GME 0.09 28.57%
More..
ASX Australia Top Losers Stocks
NSE 0.00 -100.00%
NSE 0.00 -100.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
GDY 0.01 -50.00%
SER 0.01 -50.00%
SER 0.01 -50.00%
More..

Neuren Pharmaceuticals Ltd (ASX: NEU)

NEU Technical Analysis 3
As on 17th Feb 2017 NEU Share Price closed @ 0.08 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.07 & Buy for SHORT-TERM with Stoploss of 0.07 we also expect STOCK to react on Following IMPORTANT LEVELS.
NEU Target for February
1st Target up-side 0.08
2nd Target up-side 0.08
3rd Target up-side 0.08
1st Target down-side 0.06
2nd Target down-side 0.06
3rd Target down-side 0.06
NEU Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.neurenpharma.com
NEU Address
NEU
697 Burke Road
Suite 201
Camberwell, VIC 3124
Australia
Phone: 61 3 9092 0480
NEU Latest News
Neuren completes enrolment into Phase 2 trial   NEWS.com.au   - 14th Nov 16
Neuren Pharmaceuticals Ltd advancing clinical trial for Rett syndrome   Proactive Investors Australia   - 25th Aug 16
These are the 10 worst-performing shares on the ASX in 2016   Motley Fool Australia   - 25th Jul 16
Neuren Pharmaceuticals Ltd progresses New Drug Application for Rett syndrome   Proactive Investors Australia   - 27th Jun 16
Market of Rett Syndrome Pipeline Reviewed of 14 Companies and 23 Drug Profiles   MarketWatch   - 10th Jun 16
Why the Neuren Pharmaceuticals Ltd share price has crashed today   Motley Fool Australia   - 26th Apr 16
Neuren Pharmaceuticals Ltd to reveal clinical results   Proactive Investors Australia   - 22nd Apr 16
Joseph Horrigan Joins AMO Pharma as Chief Medical Officer   PR Newswire (press release)   - 18th Apr 16
Neuren's NNZ-2566 Successful in Demonstrating Clinical Benefit in Rett ...   Marketwired (press release)   - 12th Nov 14
Neuren Pharmaceuticals makes Rett Syndrome trial breakthrough   Proactive Investors Australia   - 12th Nov 14
Interactive Technical Analysis Chart Neuren Pharmaceuticals Ltd ( NEU ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Neuren Pharmaceuticals Ltd
NEU Business Profile
Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders primarily in the United States. Its product development pipeline includes NNZ-2566 that is in Phase II clinical trials in rett syndrome, fragile X syndrome, and moderate to severe traumatic brain injury, as well as in concussion; and NNZ-2591, which is in preclinical development for chronic neurodegenerative conditions. The company has collaborative relationship with the US Army Medical Research & Materiel Command; and the Walter Reed Army Institute of Research. Neuren Pharmaceuticals Limited is based in Camberwell, Australia.